GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

IBRX · Mar 31, 2025

ImmunityBio, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001326110-25-000071General Corporate

Capex intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

6.79% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-520.10% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

41192.50% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

51.12% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

99.65% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-390.08% · CORE · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

57.74% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History9 statesHistory building

Jun 30, 20240/7 normalizedLevel 3 Sep 30, 20240/8 normalizedLevel 3 Dec 31, 20240/8 normalizedLevel 3 Mar 31, 20250/7 normalizedLevel 3 Jun 30, 20250/7 normalizedLevel 3 Sep 30, 20254/7 normalizedLevel 3 Dec 31, 20254/7 normalizedLevel 3 Mar 31, 20264/7 normalizedLevel 3 Jun 30, 20266/7 normalizedLevel 3

Period transition

What moved in the state?

Capex Intensity Decreased

Previous: 46.71%
Current: 6.79%
Delta: -39.93%

Cash Generation Increased

Previous: -2653.35%
Current: -520.10%
Delta: 2133.25%

Growth Increased

Previous: 2270.58%
Current: 41192.50%
Delta: 38921.92%

Inventory Pressure Decreased

Previous: 56.10%
Current: 51.12%
Delta: -4.98%

Margin Decreased

Previous: 100.00%
Current: 99.65%
Delta: -0.35%

Profitability Increased

Previous: -2334.23%
Current: -390.08%
Delta: 1944.15%

Sbc Intensity Decreased

Previous: 233.52%
Current: 57.74%
Delta: -175.78%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · IBRX Fundamental State →Has State · ImmunityBio, Inc. →Transitioned To · IBRX MARGIN_DECREASED →Transitioned To · IBRX PROFITABILITY_INCREASED →Transitioned To · IBRX SBC_INTENSITY_DECREASED →Transitioned To · IBRX Fundamental State →Transitioned To · IBRX CAPEX_INTENSITY_DECREASED →Transitioned To · IBRX CASH_GENERATION_INCREASED →Transitioned To · IBRX GROWTH_INCREASED →Transitioned To · IBRX INVENTORY_PRESSURE_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.